PL3125898T3 - Farmakofor do indukcji trail - Google Patents

Farmakofor do indukcji trail

Info

Publication number
PL3125898T3
PL3125898T3 PL15772254T PL15772254T PL3125898T3 PL 3125898 T3 PL3125898 T3 PL 3125898T3 PL 15772254 T PL15772254 T PL 15772254T PL 15772254 T PL15772254 T PL 15772254T PL 3125898 T3 PL3125898 T3 PL 3125898T3
Authority
PL
Poland
Prior art keywords
pharmacophore
trail induction
trail
induction
Prior art date
Application number
PL15772254T
Other languages
English (en)
Inventor
Kim D. Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of PL3125898T3 publication Critical patent/PL3125898T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15772254T 2014-03-31 2015-03-30 Farmakofor do indukcji trail PL3125898T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction
EP15772254.7A EP3125898B1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Publications (1)

Publication Number Publication Date
PL3125898T3 true PL3125898T3 (pl) 2020-11-16

Family

ID=54241169

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15772254T PL3125898T3 (pl) 2014-03-31 2015-03-30 Farmakofor do indukcji trail

Country Status (18)

Country Link
US (4) US10239877B2 (pl)
EP (2) EP3662910A1 (pl)
JP (4) JP6756435B2 (pl)
KR (2) KR102473930B1 (pl)
CN (2) CN111499636B (pl)
AU (3) AU2015241069B2 (pl)
CA (2) CA2944452C (pl)
CY (1) CY1123093T1 (pl)
DK (1) DK3125898T3 (pl)
ES (1) ES2779979T3 (pl)
HR (1) HRP20200478T1 (pl)
HU (1) HUE049013T2 (pl)
LT (1) LT3125898T (pl)
PL (1) PL3125898T3 (pl)
PT (1) PT3125898T (pl)
RS (1) RS60163B1 (pl)
SI (1) SI3125898T1 (pl)
WO (1) WO2015153468A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
LT2968294T (lt) 2013-03-13 2019-07-25 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-onas, skirtas vėžio gydymui
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
AU2014349150B2 (en) * 2013-11-15 2019-11-07 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
CN111499636B (zh) 2014-03-31 2023-01-13 斯克里普斯研究学院 用于trail诱导的药效团
SI3250208T1 (sl) * 2015-01-30 2021-01-29 Oncoceutics, Inc. 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo (1,2-A)pirido(3,4-E)pirimidin-5-(4H)-on in njegove soli ter njihova uporaba v terapiji
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
SG10202108306UA (en) * 2016-01-29 2021-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
EP3496724B8 (en) 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199A (zh) * 2023-06-02 2023-09-15 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
PL2932968T3 (pl) * 2008-06-09 2018-06-29 Allergan, Inc. Związek do leczenia stanów pośredniczonych alfa-adrenergicznie
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
EP2648517B1 (en) * 2010-12-06 2015-08-05 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
AR085817A1 (es) * 2011-03-15 2013-10-30 Chiesi Farma Spa Derivados de isoxazolidina
EP2694678A2 (en) * 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US8673923B2 (en) 2011-04-29 2014-03-18 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
LT2968294T (lt) * 2013-03-13 2019-07-25 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-onas, skirtas vėžio gydymui
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
CN111499636B (zh) * 2014-03-31 2023-01-13 斯克里普斯研究学院 用于trail诱导的药效团

Also Published As

Publication number Publication date
KR20160138513A (ko) 2016-12-05
AU2020286314A1 (en) 2021-01-21
JP2023022184A (ja) 2023-02-14
JP2017511321A (ja) 2017-04-20
EP3125898A1 (en) 2017-02-08
AU2015241069A1 (en) 2016-10-20
ES2779979T3 (es) 2020-08-21
US20190284188A1 (en) 2019-09-19
CA2944452C (en) 2022-07-19
US20220002300A1 (en) 2022-01-06
AU2015241069B2 (en) 2020-10-15
HUE049013T2 (hu) 2020-08-28
CY1123093T1 (el) 2021-10-29
JP7186256B2 (ja) 2022-12-08
EP3125898A4 (en) 2017-08-16
KR20220163533A (ko) 2022-12-09
US20170107221A1 (en) 2017-04-20
JP6873201B2 (ja) 2021-05-19
CN106456643B (zh) 2020-04-17
US10239877B2 (en) 2019-03-26
DK3125898T3 (da) 2020-03-30
JP6756435B2 (ja) 2020-09-16
WO2015153468A1 (en) 2015-10-08
RS60163B1 (sr) 2020-05-29
LT3125898T (lt) 2020-04-10
CN111499636B (zh) 2023-01-13
AU2022283729A1 (en) 2023-02-02
SI3125898T1 (sl) 2020-07-31
JP2021119157A (ja) 2021-08-12
EP3662910A1 (en) 2020-06-10
KR102611067B1 (ko) 2023-12-06
EP3125898B1 (en) 2019-12-25
US10633385B2 (en) 2020-04-28
PT3125898T (pt) 2020-04-01
US11891392B2 (en) 2024-02-06
HRP20200478T1 (hr) 2020-07-24
CN106456643A (zh) 2017-02-22
CA3158795A1 (en) 2015-10-08
CA2944452A1 (en) 2015-10-08
CN111499636A (zh) 2020-08-07
JP2020002170A (ja) 2020-01-09
US20200283440A1 (en) 2020-09-10
KR102473930B1 (ko) 2022-12-05

Similar Documents

Publication Publication Date Title
GB2531928B (en) Image-stitching for dimensioning
GB201817189D0 (en) Image-stitching for dimensioning
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201415573D0 (en) Compounds
PL3125898T3 (pl) Farmakofor do indukcji trail
GB201411418D0 (en) Compounds
GB201410430D0 (en) Compounds
GB201402431D0 (en) Compounds
GB201417369D0 (en) Compounds
GB201416186D0 (en) Compounds
GB201404987D0 (en) Compounds
GB201417561D0 (en) Compounds
GB201406591D0 (en) Compounds
GB2524311B (en) Centraliser
GB201406956D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
GB201412660D0 (en) Compounds
GB201417168D0 (en) Compounds
GB201407695D0 (en) Compounds
GB201403438D0 (en) Polymorphs
GB2525001B (en) Centraliser
GB201405361D0 (en) Compounds
GB201417832D0 (en) Compounds
GB201417829D0 (en) Compounds
GB201416116D0 (en) Compounds